Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07750158 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual Disease

Study acronym: STELLAR-316
StatusRecruiting
PhasePhase 3
SponsorExelixis
Started
View on ClinicalTrials.gov ↗

Record History

  1. Recruitment opened Trial sites expanded: 0 → 13 locations · Start date: Aug 6, 2026 to Aug 25, 2026 · Eligibility criteria expanded, about 11 words · 1 more Show 4 more changesShow less
    • Trial sites expanded: 0 → 13 locations
    • Start date: Aug 6, 2026 to Aug 25, 2026
    • Eligibility criteria expanded, about 11 words
    • Collaborators: details revised at 1 of 1 entry
  2. Interventions: MK-34574 (Biological), Placebo (Drug), Zanzalintinib (Drug) to Pembrolizumab (+) Berahyaluronidase alfa (Biological), Placebo (Drug), Zanzalintinib (Drug)v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Exelixis
25 trials monitored
See 2 trials at risk
Colorectal Cancer
2,920 trials monitored
See 132 trials at risk
The primary objective of this study is to evaluate the effectiveness of zanzalintinib + Pembrolizumab (+) berahyaluronidase alfa and zanzalintinib alone compared with placebo.
Trial Details
NCT Number NCT07750158
Lead Sponsor Exelixis
Collaborators: Merck Sharp & Dohme LLC
Conditions Colorectal Cancer
Enrollment 600 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov